peptibase
Weight Loss

Orforglipron

Also known as: LY3502970, OWL833

FDA Approved
Share:

Key Facts: Orforglipron

Category
Weight Loss
FDA Status
FDA Approved
Clinical Status
FDA Approved (April 2026) - Obesity/overweight with comorbidities. Brand name: Foundayo. First oral GLP-1 for weight loss with no food/water restrictions.
Administration
Oral tablet daily
Typical Dose
Limited community data available
Frequency
See research protocols
Duration
Long-term use expected
Also Known As
LY3502970, OWL833

Mechanism of Action

Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide.

Research Summary

ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program - the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical Dosingⓘ

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Not yet FDA approved (decision expected April 2026). If approved, Lilly has announced LillyDirect pricing: $149-$399/month self-pay depending on dose.

Research Dosingⓘ

Scientific studies

Doses from clinical trials

Duration

Long-term use expected

Administration

Oral tablet daily

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Diarrhea (19-26%)
  • ●Nausea (13-18%)
  • ●Vomiting
  • ●GI events mild-moderate
  • ●Pulse increase
  • ●Investigational - not yet approved

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does Orforglipron do?

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

How does Orforglipron work?

Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide.

Is Orforglipron FDA approved?

Yes, Orforglipron is FDA approved. FDA Approved (April 2026) - Obesity/overweight with comorbidities. Brand name: Foundayo. First oral GLP-1 for weight loss with no food/water restrictions.

What are the side effects of Orforglipron?

Reported side effects include: Diarrhea (19-26%), Nausea (13-18%), Vomiting, GI events mild-moderate, Pulse increase. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Orforglipron?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Oral tablet daily. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Orforglipron or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

Exenatide

FDA

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss
How to Use OrforglipronOrforglipron AlternativesCompare with SimilarBrowse All Peptides

Want updates on Orforglipron research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides